Leaflet: information for the user
Icandra 50mg/850mg film-coated tablets
Icandra 50mg/1000mg film-coated tablets
vildagliptin/hydrochloride of metformin
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
1.What is Icandra and what it is used for
2.What you need to know before starting to take Icandra
3.How to take Icandra
4.Possible side effects
5.Storage of Icandra
6.Contents of the pack and additional information
The active principles of Icandra, vildagliptin and metformin,belong to a group of medications called “oral antidiabetics”.
Icandrais used to treat adult patients with type2 diabetes. This type of diabetes is also known as non-insulin dependent diabetes mellitus. Icandra is used when diabetes cannot be controlled with diet and exercise alone and/or with other medications used to treat diabetes (insulin or sulfonylureas).
Type2 diabetes appears if the body does not produce enough insulin or if the insulin produced does not work properly. It can also appear if the body produces too much glucagon.
Insulin and glucagon are produced in the pancreas. Insulin helps to reduce blood sugar levels, especially after meals. Glucagon promotes the production of sugar by the liver and causes blood sugar levels to increase.
How Icandra works
Both active principles, vildagliptin and metformin, help to control blood sugar levels. The active principle vildagliptin stimulates the pancreas to produce more insulin and less glucagon. The active principle metformin helps the body to use insulin better.This medication has been shown to reduce blood sugar, which will help to prevent complications of your diabetes.
Do not take Icandra
Warnings and precautions
Risk of lactic acidosis
Icandra may cause a rare but serious side effect called lactic acidosis, especially if your kidneys do not function properly. The risk of developing lactic acidosis is also increased with uncontrolled diabetes, severe infections, prolonged fasting or alcohol consumption, dehydration (see below for more information), liver problems, and any medical condition in which a part of the body has a reduced oxygen supply (such as acute and severe heart diseases).
If any of the above applies to you, consult your doctor for further instructions.
Stop taking Icandra for a short period of time if you have a condition that may be associated with dehydration (significant loss of body fluids), such as intense vomiting, diarrhea, fever, exposure to heat, or if you drink less fluid than normal. Consult your doctor for further instructions.
Stop taking Icandra and contact a doctor or the nearest hospital immediately if you experience any of the symptoms that produce lactic acidosis , as this condition can lead to coma.
The symptoms of lactic acidosis include:
Lactic acidosis is a medical emergency and should be treated in a hospital.
Icandra is not a substitute for insulin. Therefore, do not take Icandra for the treatment of type 1 diabetes.
Consult your doctor, pharmacist, or nurse before starting to take Icandra if you have or have had a pancreatic disease.
Consult your doctor, pharmacist, or nurse before starting to take Icandra if you are taking a diabetes medication known as a sulfonylurea. Your doctor may want to reduce your sulfonylurea dose when taken together with Icandra to avoid low blood sugar (hypoglycemia).
If you have previously taken vildagliptin but had to stop taking it due to liver disease, do not take this medication.
Skin lesions are common complications of diabetes. Follow the recommendations of your doctor or nurse for skin and foot care and pay special attention to the appearance of blisters or ulcers while taking Icandra. If this occurs, you should consult your doctor immediately.
If you need to undergo major surgery, stop taking Icandra while the procedure is being performed and for a period of time afterwards. Your doctor will decide when to interrupt Icandra treatment and when to restart it.
Liver function tests should be performed before starting Icandra treatment, at intervals of three months during the first year, and periodically thereafter . This is done to detect as soon as possible any sign indicating an increase in liver enzymes (transaminases).
During Icandra treatment, your doctor will check your kidney function at least once a year or more frequently if you are an elderly person and/or if your kidney function is deteriorating.
Your doctor will periodically check your blood sugar levels and urine.
Children and adolescents
The administration of Icandra is not recommended in children and adolescents under 18 years.
Other medications and Icandra
If you need to be administered an injection of a contrast medium containing iodine, for example, in the context of a radiography or an examination, stop taking Icandra before the injection or at the time of the injection. Your doctor will decide when to interrupt Icandra treatment and when to restart it.
Inform your doctor if you are taking, have taken recently, or may need to take any other medication. You may need more frequent blood sugar and kidney function tests, or your doctor may need to adjust the dose of Icandra. It is especially important to mention the following:
Taking Icandra with alcohol
Avoid excessive alcohol consumption while taking Icandra, as this may increase the risk of lactic acidosis (see section "Warnings and precautions").
Pregnancy and breastfeeding
Consult your doctor or pharmacist before using any medication.
Driving and operating machinery
If you feel dizzy while taking Icandra, do not drive or operate tools or machinery.
The dose of Icandra that each person should take varies depending on their condition. Your doctor will tell you exactly the dose of Icandra that you should take.
Follow exactly the administration instructions for this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
The recommended dose is a film-coated tablet of 50mg/850mg or 50mg/1000mg twice a day.
If you have reduced renal function, your doctor may prescribe a lower dose. Your doctor may also prescribe a lower dose if you are taking a diabetes medication known as a sulfonylurea.
Your doctor may prescribe this medication alone or in combination with certain medications that lower blood sugar levels.
Form of Use of Icandra
Follow your doctor's dietary advice. In particular, if you are following a weight control diet for diabetics, continue with the diet while taking Icandra.
If You Take MoreIcandraThan You Should
If you have taken too many Icandra tablets, or if someone else has taken your tablets,consult your doctor or pharmacist immediately.You may need medical attention. If you need to visit a doctor or go to the nearest hospital, bring the packaging and this leaflet with you.
If You Forget to TakeIcandra
If you forget to take a tablet, take it with the next meal, unless it is already time to take the usual dose. Do not take a double dose (two tablets at once) to make up for the missed doses.
If You Interrupt Treatment with Icandra
Continue taking this medication as long as your doctor prescribes it for you so that they can continue to monitor your blood sugar levels. Do not stop taking Icandra unless your doctor tells you to. If you have any doubts about the duration of treatment, consult your doctor.
If you have any other questions about the use of this medication, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
You muststop taking Icandra andvisit your doctor immediatelyif you experience any of the following side effects:
Other side effects
Some patients have experienced the following side effects while taking Icandra:
Since the marketing of this product, the following side effects have also been reported:
Reporting side effects
If you experienceany type of side effect, consult your doctor, pharmacist, or nurse, even if it is apossibleside effect that does not appear in this leaflet.You can also report themdirectly through thenational notification system included in theAppendix V. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Appearance of the product and contents of the pack
Icandra 50 mg/850 mg film-coated tablets are yellow, oval-shaped tablets with “NVR” on one face and “SEH” on the other.
Icandra 50 mg/1000 mg film-coated tablets are dark yellow, oval-shaped tablets with “NVR” on one face and “FLO” on the other.
Icandra is available in packs containing 10, 30, 60, 120, 180, or 360 film-coated tablets, and in multiple packs containing 120 (2 x 60), 180 (3 x 60), or 360 (6 x 60) film-coated tablets.It may only be marketed in certain pack sizes and doses in your country.
Marketing authorisation holder
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland
Responsible person for manufacturing
Lek d.d, PE PROIZVODNJA LENDAVA
Trimlini 2D
Lendava, 9220
Slovenia
Novartis Pharma GmbH
Roonstrasse 25
D-90429 Nürnberg
Germany
Novartis Pharmaceutical Manufacturing LLC
Verovškova ulica 57
1000 Ljubljana
Slovenia
Novartis Farmacéutica, S.A.
Gran Via de les Corts Catalanes, 764
08013 Barcelona
Spain
Novartis Pharma GmbH
Sophie-Germain-Strasse 10
90443 Nürnberg
Germany
You can obtain more information about this medicinal product by contacting the local representative of the marketing authorisation holder:
België/Belgique/Belgien Novartis Pharma N.V. Tél/Tel: +32 2 246 16 11 | Lietuva SIA Novartis Baltics Lietuvos filialas Tel: +370 5 269 16 50 |
???????? Novartis Bulgaria EOOD ???.: +359 2 489 98 28 | Luxembourg/Luxemburg Novartis Pharma N.V. Tél/Tel: +32 2 246 16 11 |
Ceská republika Novartis s.r.o. Tel: +420 225 775 111 | Magyarország Novartis Hungária Kft. Tel.: +36 1 457 65 00 |
Danmark Novartis Healthcare A/S Tlf: +45 39 16 84 00 | Malta Novartis Pharma Services Inc. Tel: +3562122 2872 |
Deutschland Novartis Pharma GmbH Tel: +49 911 273 0 | Nederland Novartis Pharma B.V. Tel: +31 88 04 52 111 |
Eesti SIA Novartis Baltics Eesti filiaal Tel: +37266 30 810 | Norge Novartis Norge AS Tlf: +47 23 05 20 00 |
Ελλ?δα Novartis (Hellas) A.E.B.E. Τηλ: +30 210 281 17 12 | Österreich Novartis Pharma GmbH Tel: +43 1 86 6570 |
España Laboratorios Gebro Pharma, S.A. Tel: +34 93 205 86 86 | Polska Novartis Poland Sp. z o.o. Tel.: +48 22 375 4888 |
France Novartis Pharma S.A.S. Tél: +33 1 55 47 66 00 | Portugal Laboratório Normal – Produtos Farmacêuticos Lda. Tel. +351 21000 8600 |
Hrvatska Novartis Hrvatska d.o.o. Tel. +385 1 6274 220 | România Novartis Pharma ServicesRomania SRL Tel: +40 21 31299 01 |
Ireland Novartis Ireland Limited Tel: +353 1 260 12 55 | Slovenija Novartis Pharma Services Inc. Tel: +386 1 300 75 50 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika Novartis Slovakia s.r.o. Tel: +421 2 5542 5439 |
Italia Novartis Farma S.p.A. Tel: +39 02 96 54 1 | Suomi/Finland Novartis Finland Oy Puh/Tel:+358 (0)10 6133 200 |
Κ?προς Novartis Pharma Services Inc. Τηλ: +357 22 690 690 | Sverige Novartis Sverige AB Tel: +46 8 732 32 00 |
Latvija SIA Novartis Baltics Tel: +371 67 887 070 |
Last update date of this leaflet:
Other sources of information
The detailed information on this medicinal product is available on the website of the European Medicines Agency: http://www.ema.europa.eu
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.